Changes To Part D Protected Classes Uniformly Opposed At House Hearing
This article was originally published in The Pink Sheet Daily
In a hearing on CMS’ proposed Medicare Part D rule, members of the Energy & Commerce Health Subcommittee agreed that the potential cost savings to Medicare through its plan to remove antidepressants, antipsychotics and immunosuppressants from Part D “protected class” status do not outweigh the downside for beneficiaries.
You may also be interested in...
Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’